128 related articles for article (PubMed ID: 12556701)
1. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
Seaton RA; Fox R; Bodasing N; Peters SE; Gourlay Y
AIDS; 2003 Feb; 17(3):445-7. PubMed ID: 12556701
[No Abstract] [Full Text] [Related]
2. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
3. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
Moyle GJ
AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
[No Abstract] [Full Text] [Related]
4. Trizivir on the market.
Kerr C
Trends Microbiol; 2001 Jan; 9(1):13. PubMed ID: 11166234
[No Abstract] [Full Text] [Related]
5. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
6. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
Keiser P; Nassar N
Expert Opin Pharmacother; 2007 Mar; 8(4):477-83. PubMed ID: 17309342
[TBL] [Abstract][Full Text] [Related]
7. AIDS drug in halted trial less effective as monotherapy.
AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364
[No Abstract] [Full Text] [Related]
8. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
Latham V; Stebbing J; Mandalia S; Michailidis C; Davies E; Bower M; Gazzard B; Nelson M
J Antimicrob Chemother; 2005 Jul; 56(1):186-9. PubMed ID: 15911551
[TBL] [Abstract][Full Text] [Related]
9. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
Porche D
J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
11. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine/zidovudine/abacavir: triple combination tablet.
Ibbotson T; Perry CM
Drugs; 2003; 63(11):1089-98; discussion 1099-1100. PubMed ID: 12749741
[TBL] [Abstract][Full Text] [Related]
13. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.
Clotet B; Carmena J; Pulido F; Luque I; Rodriguez-Alcántara F;
HIV Clin Trials; 2004; 5(1):33-9. PubMed ID: 15002085
[TBL] [Abstract][Full Text] [Related]
14. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
[TBL] [Abstract][Full Text] [Related]
15. Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen.
Shaefer MS
Ann Pharmacother; 2004; 38(7-8):1314-6. PubMed ID: 15187204
[No Abstract] [Full Text] [Related]
16. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Moyle GJ; Gazzard BG
AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
[No Abstract] [Full Text] [Related]
17. AIDS foundation seeks withdrawal of approval for HIV drug combination.
Clarke B
Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
[No Abstract] [Full Text] [Related]
18. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
19. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
